Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7195MR)

This product GTTS-WQ7195MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7195MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14901MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ13212MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ4466MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ9967MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ8757MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ7541MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ13303MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ7647MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW